JACKSONVILLE, Fla., June 11, 2008 (PRIME NEWSWIRE) -- BodyTel Scientific Inc. (OTCBB:BDYT), a developer of wireless telemedical devices, is pleased to report that GlucoTel was awarded with the German Industrial 2008 "Initiative Mittelstand" award in the medical technology category. An independent panel composed of professors, scientists, technical editors and industry experts had to review 1,600 submissions in 21 different categories. The jury assessed the blood glucose monitoring and diabetes management system, GlucoTel, and deemed the product as extremely innovative and technologically compelling.
In addition to receiving the award PR package, BodyTel can now also present a medallion recognizing the award on its corporate website and on all documents related to the product advertising. The German "Initiative Mittelstand's" goal is to offer a reliable source of independent information and to inform people about the potential of new technologies from various medical and technology sectors.
"We are very proud of the publicity that this award brings," said Stefan Schraps, CEO of BodyTel Scientific. "As we begin our sales and marketing efforts, it is important to have independent references from well-recognized institutions to introduce our GlucoTel system to a broader audience."
The GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and doctors in the treatment of diabetes and its corollary diseases. GlucoTel electronically measures the blood sugar level and then sends it automatically via Bluetooth to the patient's cell phone. After that, the data is automatically transmitted from the cell phone to an online database via mobile internet connection and stored on a long-term basis in the patient's profile. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or caregivers, can access the database 'BodyTel Center' at www.bodytel.com via the internet at any time using a secure login.
Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur. Forward-looking statements in this news release include: As we begin our sales and marketing efforts it is important to have independent references from well recognized institutions to introduce our GlucoTel system to a broader audience. It is important to note that the Company's actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company's Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company's periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC's website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events